100 Migraine drugs, A to Z: Almotriptan

April 20, 2018

Almotriptan (Axert) belongs to the family of triptans, which are, by far, the most effective drugs for the acute treatment of migraine headaches.

The first drug in this category, sumatriptan (Imitrex) was introduced in 1992 as an injection. Sumatriptan injection remains the most effective treatment – it works for 80% of migraine sufferers. The tablets of sumatriptan and other triptans are a bit less effective, but still provide good relief for over 60% of patients. For some, combining a triptan with 400 mg of ibuprofen (Advil, Motrin) or 500 mg of naproxen (Aleve, Naprosyn, Anaprox) makes it much more effective.

Almotriptan is one of the five relatively fast-acting triptans. The other four are sumatriptan, rizatriptan (Maxalt), zolmitriptan (Zomig), and eletriptan (Relpax). Naratriptan (Amerge) and especially frovatriptan (Frova) take longer to begin helping, but their effect tends to last longer.

In Europe, many triptans are sold without a prescription, which indicates that these are very safe drugs. There is no evidence that triptans cause medication overuse headaches (unlike caffeine and opioid/narcotoc drugs). See my post on daily use of triptans and a recent article debunking the myth of medication overuse headaches.

Written by
Alexander Mauskop, MD
Continue reading
June 7, 2026
News
A new edition of my migraine book and an upcoming conversation with Dr. Sanjay Gupta
An overview of why I updated The End of Migraines: 150 Ways to Stop Your Pain for a 3rd edition, what has changed in migraine treatment, and how a more structured, realistic approach can help people who feel they’ve “tried everything.”
Read article
June 4, 2026
Research
A New Study of Meat Intake, Genetics, and Brain Health
A newly published Swedish study suggests that the relationship between diet and brain aging may be more genetically specific than previously understood. Researchers followed over 2,000 older adults for up to 15 years and found that higher meat consumption was associated with slower cognitive decline and lower dementia risk, but only in those carrying the APOE E4 genetic variant, the most common hereditary risk factor for Alzheimer's disease. This may be relevant for people with headaches.
Read article
June 3, 2026
News
Keynote address at the 22nd Annual Neuroscience Zappulla Research Day
I was honored to be delivering the keynote address at the 22nd Annual Neuroscience Zappulla Research Day on Wednesday, June 3, at the Hackensack Meridian Neuroscience Institute, JFK University Medical Center in Edison, NJ.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe